CHMP recommends marketing authorisation for Lisonorm
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that a marketing authorisation be granted for Gedeon Richter's Lisonorm (amlodipine plus lisinopril), which is indicated as a substitution therapy for patients with blood pressure adequately controlled with lisinopril and amlodipine.